Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Sanofi-GSK's Beta-Containing COVID-19 Vaccine Shows Efficacy Against Omicron

  • Sanofi SA (NASDAQ:SNY) and GSK plc (NYSE:GSK) have announced positive data from their vaccine trial of adjuvanted bivalent D614 and Beta (B.1.351) vaccine candidate. 
  • "Sanofi-GSK's vaccine is the first candidate to demonstrate efficacy in a placebo-controlled trial in an environment of high Omicron variant circulation," Sanofi said in a statement.
  • The bivalent vaccine targets the beta variant and the original strain of the virus.
  • Related: Sanofi-GSK's Next-Gen COVID-19 Booster Shows Potential Against Variants Of Concern.
  • In a trial involving 13,000 adults, the vaccine demonstrated an efficacy rate of 64.7% against symptomatic COVID and 72% against infections specifically caused by the omicron variant.
  • When used in people who previously had COVID, the results were stronger. The vaccine generated an efficacy rate of 75.1% against symptomatic COVID and 93.2% in omicron-confirmed symptomatic cases.
  • The new data supporting the bivalent vaccine will be submitted to regulatory authorities.
  • Sanofi and GSK's original COVID-19 vaccine is already under review by the European Medicines Agency.
  • Price Action: SNY shares are up 3.27% at $52.07, and GSK stock is up 1.01% at $43.18 during the premarket session on the last check Friday.
  • Photo by Gerd Altmann from Pixabay
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.